Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

Survival of patients with completely resected non-small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established. This phase III study assessed the impact of postoperative adjuvant gefitinib on overall survival (OS). Patients with completely r...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 31; číslo 27; s. 3320
Hlavní autoři:	Goss, Glenwood D, O'Callaghan, Chris, Lorimer, Ian, Tsao, Ming-Sound, Masters, Gregory A, Jett, James, Edelman, Martin J, Lilenbaum, Rogerio, Choy, Hak, Khuri, Fadlo, Pisters, Katherine, Gandara, David, Kernstine, Kemp, Butts, Charles, Noble, Jonathan, Hensing, Thomas A, Rowland, Kendrith, Schiller, Joan, Ding, Keyue, Shepherd, Frances A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.09.2013
Témata:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy, Adjuvant Disease-Free Survival Double-Blind Method Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - surgery Male Neoplasm Staging Placebos Prospective Studies Quinazolines - adverse effects Quinazolines - therapeutic use Survival Rate Treatment Outcome
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!